Viveve Medical, Inc.

Good afternoon and welcome to Vaviv's third quarter 2021 financial results and corporate update conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. Please note this event is being recorded. I will now turn the call over to Jeannie Swindle, Vaviv's Senior Director of Corporate Communications. Please go ahead.

Thank you, Operator, and welcome, everyone. Before we begin, we would like to remind you that this conference call may contain forward-looking statements regarding future events or the company's future financial performance. Any statement that is not a statement of historical fact is forward-looking. This includes remarks about the corporation's projections, expectations, plans, beliefs and prospects. These statements are based on judgments and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are described more fully in the company's annual report on Form 10-K and other filings made with the SEC, which are also available on the company's website. Also, any forward-looking statements represent management's view only as of the date of this conference call and should not be relied upon as representing management's views as of any subsequent date. Speaking on today's call will be Scott Durbin, the VEEV's CEO, and Jim Robbins, Senior Vice President of Finance and Administration. I will now turn the call over to Jim.

Thank you, Jeannie. Good afternoon, everyone, and thank you for joining the call today. I will begin today's call with a brief review of our third quarter 2021 financial results. I will then turn the call over to Scott, who will provide a corporate update. Today, we reported total revenue for the third quarter of $1.6 million from the global sale of 16 systems and approximately 2,300 consumable treatment tips. As of the end of the third quarter 2021, the company had an installed base of 870 VIVI systems worldwide. Third quarter total operating expenses were $5.6 million compared to $3.6 million for the same period last year. The increase is mainly a result of the company's efforts to advance our stress urinary incontinence, our SUI clinical development program, and the pivotal pursuit trial in the US. We ended the quarter in a strong cash position due to our continuing operational measures to manage our cash burn. As of September 30th, 2021, We reported cash and cash equivalents of $22.7 million. Thanks. I'll now turn the conference call over to Scott.